Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma - Concepedia

Concepedia

Publication | Open Access

Mean Platelet Volume/Platelet Count Ratio and Risk of Progression in Glioblastoma

DOI Full Paper Access

13

Citations

39

References

2021

Year

Johannes Wach, Stefanos Apallas, Matthias Schneider, Johannes Weller, Patrick Schuss, Hartmut Vatter, Ulrich Herrlinger, Erdem Güresir

Frontiers in Oncology

Abstract

MPV/PC ratio may independently predict the progression-free survival rates of patients with glioblastoma multiforme.

References

	Year	Citations
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010 Quinn T. Ostrom, Haley Gittleman, P Farah, Neuro-Oncology	2013	12.1K
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Roger Stupp, Monika E. Hegi, Warren Mason, The Lancet Oncology 5-Year AnalysisNeuro-oncologyOncologyRadiation TherapyAdjuvant Temozolomide	2009	7.7K
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia, New England Journal of Medicine	2005	7.1K
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments Brain Pathology	2009	4K
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival Michel Lacroix, Dima Abi-Said, Daryl R. Fourney, Journal of neurosurgery	2001	3K
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2005-2009 Therese A. Dolecek, Jennifer M. Propp, N. E. Stroup, Neuro-Oncology	2012	1.7K
Isocitrate Dehydrogenase 1 Codon 132 Mutation Is an Important Prognostic Biomarker in Gliomas Marc Sanson, Yannick Marie, Sophie Paris, Journal of Clinical Oncology	2009	993
Neurosurgical Outcomes in a Modern Series of 400 Craniotomies for Treatment of Parenchymal Tumors Raymond Sawaya, Maarouf A. Hammoud, Derek Schoppa, Neurosurgery	1998	619
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial Ulrich Herrlinger, Theophilos Tzaridis, Frederic Mack, The Lancet Hematological MalignancyNeuro-oncologyTreatment StrategiesMedicineStandard Temozolomide Therapy	2019	556
Prognostic factors for survival of patients with glioblastoma: Recursivepartitioning analysis Kathleen R. Lamborn, Susan M. Chang, Michael D. Prados Neuro-Oncology	2004	549

Page 1